Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIA | Q9BZP6 | 17/20 | 0.64 |
| ▸ | CHIT1 | Q13231 | 16/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18586427 | 1.00 | CHIA (0.64) | CHIACHIT1KCNH2L3MBTL1FPR2 | |
| Hydrochloric Acid SCHEMBL18577386 | 0.99 | CHIA (0.63) | CHIACHIT1KCNH2L3MBTL1FPR2 | |
| Hydrochloric Acid SCHEMBL18577385 | 0.99 | CHIA (0.63) | CHIACHIT1KCNH2L3MBTL1FPR2 | |
| SCHEMBL18577080 | 0.84 | CHIT1 (0.61) | CHIACHIT1KCNH2L3MBTL1 | |
| SCHEMBL18586810 | 0.84 | CHIT1 (0.61) | CHIACHIT1KCNH2L3MBTL1 | |
| SCHEMBL18610273 | 0.83 | CHIT1 (0.62) | CHIACHIT1KCNH2 | |
| SCHEMBL18608069 | 0.83 | CHIT1 (0.62) | CHIACHIT1KCNH2 | |
| SCHEMBL18589493 | 0.83 | CHIT1 (0.62) | CHIACHIT1KCNH2 | |
| SCHEMBL18607793 | 0.83 | CHIT1 (0.62) | CHIACHIT1KCNH2 | |
| Hydrochloric Acid SCHEMBL18577310 | 0.82 | CHIT1 (0.61) | CHIACHIT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| EP-3344616-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS S.A. (PL) | 2018-07-11 | — | — | EP | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | CHIA 1/4885CHIT1 2/4885KCNH2 3882/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | CHIA 1/4885CHIT1 2/4885KCNH2 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.